Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Environmental Compliance and Pharmaceutical Quality Standards Pave the Way for Transformational Growth in Chromatography 2024-08-13 01:30
OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship 2024-08-12 22:01
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA 2024-08-12 22:00
Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights 2024-08-12 21:52
VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism 2024-08-12 21:00
Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial 2024-08-12 20:30
IASO Bio Receives U.S. FDA Approval of Investigational New Drug Application for Equecabtagene Autoleucel for Two New Autoimmune Disease Indications 2024-08-12 13:52
Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024 2024-08-12 10:18
T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors 2024-08-08 20:00
Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States 2024-08-07 20:00
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC) 2024-08-07 19:00
Docquity Drives Demand for SIT Pharma's Duo Probiotics in Thailand, Achieving 31% Sales Growth in 6 months 2024-08-07 10:05
GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer 2024-08-07 09:00
Senhwa Biosciences receives US FDA Study May Proceed letter for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors 2024-08-07 08:49
Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner 2024-08-06 19:00
Latest Updates of Viva Biotech's Portfolio Companies 2024-08-06 18:47
First patient enrollment in the U.S. - A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis 2024-08-06 17:00
First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome 2024-08-06 12:44
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia 2024-08-06 08:00
Everest Medicines to Announce 2024 Interim Results on August 28, 2024 2024-08-06 07:30
1 19 20 21 22 23 412